Metabolic engineering of Escherichia coli for N-methylserotonin biosynthesis,Metabolic Engineering

当前位置： X-MOL 学术 › Metab. Eng. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Metabolic engineering of Escherichia coli for N-methylserotonin biosynthesis
Metabolic Engineering ( IF 6.8 ) Pub Date : 2024-11-25 , DOI: 10.1016/j.ymben.2024.11.011
Qingchen Li, Chenxi Li, Jie Zhong, Yukun Wang, Qinghua Yang, Bingmei Wang, Wenjin He, Jianzhong Huang, Shengyuan Lin, Feng Qi

N-methylserotonin (NMS) is a valuable indole alkaloid with therapeutic potential for psychiatric and neurological disorders, and it is used in health foods, cosmetics, and weight loss supplements. However, environmental challenges and low reaction efficiencies significantly hinder cost-effective, large-scale production of NMS in plants or through chemical synthesis. Herein, we have successfully engineered Escherichia coli strains to enhance NMS production from L-tryptophan using whole-cell catalysis. We developed multiple biosynthesis pathways incorporating modules for serotonin (5-hydroxytryptamine, 5-HT), tetrahydromonapterin (MH₄), and S-adenosylmethionine (SAM) synthesis. To enhance MH₄ availability, we employed a high-activity Bacillus subtilis FolE and minimized carbon flux loss through targeted gene knockouts in competitive metabolic pathways, improving 5-HT production. Additionally, we constructed a comprehensive SAM biosynthesis module to facilitate transmethylation by a selected N-methyltransferase fused with ProS2. These engineered modules were coexpressed in two plasmids within the optimized strain NMS-19, producing 128.6 mg/L of NMS in a 5-L bioreactor using fed-batch cultivation—a 92-fold increase over the original strain. This study introduces a viable strategy for NMS production and provides insights into the biosynthesis of SAM-dependent methylated tryptamine derivatives.

更新日期：2024-11-25

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南